These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31483796)

  • 1. Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries.
    Naber SK; Knudsen AB; Zauber AG; Rutter CM; Fischer SE; Pabiniak CJ; Soto B; Kuntz KM; Lansdorp-Vogelaar I
    PLoS One; 2019; 14(9):e0220234. PubMed ID: 31483796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population.
    Knudsen AB; Lansdorp-Vogelaar I; Rutter CM; Savarino JE; van Ballegooijen M; Kuntz KM; Zauber AG
    J Natl Cancer Inst; 2010 Aug; 102(16):1238-52. PubMed ID: 20664028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis.
    Lansdorp-Vogelaar I; Kuntz KM; Knudsen AB; Wilschut JA; Zauber AG; van Ballegooijen M
    Ann Intern Med; 2010 Sep; 153(6):368-77. PubMed ID: 20855801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With a Blood Test That Meets the Centers for Medicare & Medicaid Services Coverage Decision.
    van den Puttelaar R; Nascimento de Lima P; Knudsen AB; Rutter CM; Kuntz KM; de Jonge L; Escudero FA; Lieberman D; Zauber AG; Hahn AI; Inadomi JM; Lansdorp-Vogelaar I
    Gastroenterology; 2024 Jul; 167(2):368-377. PubMed ID: 38552671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population.
    Ebner D; Kisiel J; Barnieh L; Sharma R; Smith NJ; Estes C; Vahdat V; Ozbay AB; Limburg P; Fendrick AM
    J Med Econ; 2023; 26(1):1219-1226. PubMed ID: 37752872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force.
    Knudsen AB; Zauber AG; Rutter CM; Naber SK; Doria-Rose VP; Pabiniak C; Johanson C; Fischer SE; Lansdorp-Vogelaar I; Kuntz KM
    JAMA; 2016 Jun; 315(23):2595-609. PubMed ID: 27305518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
    Ladabaum U; Mannalithara A
    Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Simulated Outcomes Between Stool- and Blood-Based Colorectal Cancer Screening Tests.
    Fendrick AM; Vahdat V; Chen JV; Lieberman D; Limburg PJ; Ozbay AB; Kisiel JB
    Popul Health Manag; 2023 Aug; 26(4):239-245. PubMed ID: 37466476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
    Sharma T
    Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population health outcomes of blood-based screening for colorectal cancer in comparison to current screening modalities: insights from a discrete-event simulation model incorporating longitudinal adherence.
    Forbes SP; Yay Donderici E; Zhang N; Sharif B; Tremblay G; Schafer G; Raymond VM; Talasaz A; Eagle C; Das AK; Grady WM
    J Med Econ; 2024; 27(1):991-1002. PubMed ID: 39037853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimated impact and value of blood-based colorectal cancer screening at varied adherence compared with stool-based screening.
    Kisiel JB; Fendrick AM; Ebner DW; Ozbay AB; Vahdat V; Estes C; Limburg PJ
    J Med Econ; 2024; 27(1):746-753. PubMed ID: 38686394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model.
    Piscitello A; Saoud L; Fendrick AM; Borah BJ; Hassmiller Lich K; Matney M; Ozbay AB; Parton M; Limburg PJ
    PLoS One; 2020; 15(12):e0244431. PubMed ID: 33373409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Waiving Coinsurance for Follow-Up Colonoscopy after a Positive Stool-Based Colorectal Screening Test in a Medicare Population.
    Fendrick AM; Lieberman D; Vahdat V; Chen JV; Ozbay AB; Limburg PJ
    Cancer Prev Res (Phila); 2022 Oct; 15(10):653-660. PubMed ID: 35768200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare.
    Ladabaum U; Mannalithara A; Brill JV; Levin Z; Bundorf KM
    Am J Gastroenterol; 2018 Dec; 113(12):1836-1847. PubMed ID: 29904156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population.
    Fisher DA; Karlitz JJ; Jeyakumar S; Smith N; Limburg P; Lieberman D; Fendrick AM
    J Med Econ; 2021; 24(1):654-664. PubMed ID: 33902366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes.
    Fendrick AM; Fisher DA; Saoud L; Ozbay AB; Karlitz JJ; Limburg PJ
    Cancer Prev Res (Phila); 2021 Sep; 14(9):845-850. PubMed ID: 34021023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Eliminating Cost-Sharing by Medicare Beneficiaries for Follow-Up Colonoscopy After a Positive Stool-based Colorectal Cancer Screening Test.
    Fendrick AM; Lieberman D; Chen JV; Vahdat V; Ozbay AB; Limburg PJ
    Cancer Res Commun; 2023 Oct; 3(10):2113-2117. PubMed ID: 37787758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With Blood-Based Biomarkers (Liquid Biopsy) vs Fecal Tests or Colonoscopy.
    Ladabaum U; Mannalithara A; Weng Y; Schoen RE; Dominitz JA; Desai M; Lieberman D
    Gastroenterology; 2024 Jul; 167(2):378-391. PubMed ID: 38552670
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.